quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:44:26·982d
NEWSRelease
Royal Caribbean Cruises Ltd. logo
Sigilon Therapeutics Inc. logo
Sarepta Therapeutics Inc. logo

Over $25M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying

RCL· Royal Caribbean Cruises Ltd.SGTX· Sigilon Therapeutics Inc.SRPT· Sarepta Therapeutics Inc.
Consumer DiscretionaryHealth Care
Original source

Companies

  • RCL
    Royal Caribbean Cruises Ltd.
    Consumer Discretionary
  • SGTX
    Sigilon Therapeutics Inc.
    Health Care
  • SRPT
    Sarepta Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jan 28SRPTUpdateBarclays$20.00
  • Dec 9SRPTUpdateWedbush$32.00
  • Nov 5SRPTUpdateMizuho$26.00
  • Sep 22SRPTUpdateBMO Capital Markets$50.00
  • Jul 29SRPTUpdateBarclays$22.00
  • Jul 29SRPTUpdateBernstein$13.00

Related

  • PR1d
    Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
  • PR3d
    When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
  • SEC6d
    SEC Form DEFA14A filed by Royal Caribbean Cruises Ltd.
  • SEC6d
    SEC Form DEF 14A filed by Royal Caribbean Cruises Ltd.
  • PR9d
    /C O R R E C T I O N -- Silversea Cruises/
  • PR9d
    A PACIFIC AWAKENING: SIX EXCLUSIVE EVENTS HEADLINE SILVERSEA'S NEW 125-DAY WORLD CRUISE 2029
  • PR14d
    ROYAL CARIBBEAN GROUP TO HOLD CONFERENCE CALL ON FIRST QUARTER 2026 EARNINGS
  • PR15d
    THE MOST REWARDING LOYALTY PROGRAM IN LUXURY CRUISING: SILVERSEA ENHANCES ITS VENETIAN SOCIETY WITH NEW LOYALTY TIERS AND ENHANCED BENEFITS
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022